Drugs / ZERIPATAMIG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04806035 | Apr 2021 → Jun 2024 | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma +1 | TG Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03804996 | Mar 2019 → Feb 2024 | lymphoma | TG Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZERIPATAMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650425 ↗ |
| Known as | TG-1801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04806035 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650425 ↗ |
| Route | Intravenous | “Intravenous infusion over 1 hour every 4 weeks” NCT03804996 ↗ |
| Target | CD19 | “It is a bispecific, first-in-class, CD47 and CD19 antibody” NCT04806035 ↗ |
| Target | CD47 | “It is a bispecific, first-in-class, CD47 and CD19 antibody” NCT04806035 ↗ |